mHealth Smartphone App and Postpartum Glucose Intolerance for Patients With GDM (NCT05597943) | Clinical Trial Compass
CompletedNot Applicable
mHealth Smartphone App and Postpartum Glucose Intolerance for Patients With GDM
United States30 participantsStarted 2023-05-01
Plain-language summary
Without intervention, approximately 70% of women diagnosed with GDM will develop type 2 diabetes mellitus in their lifetime. Abnormal results of a 2 hour oral glucose tolerance test (OGTT) performed as early as 2 days postpartum are predictive of impaired glucose tolerance 1 year postpartum. The investigators hypothesize that use of the Malama smartphone application to optimize antenatal glycemic control will result in lower incidence of postpartum glucose intolerance, which may decrease long term risk of progression to diabetes mellitus.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Pregnant women receiving prenatal, delivery, and postpartum care at Tufts Medical Center
✓. Gestational diabetes diagnosed between 14 0/7 and 31 6/7 weeks gestation on basis of 1-hour glucose challenge test result of \>=200 mg/dL or Carpenter-Coustan criteria
✓. \>= 18 years of age
✓. Literate in English or Spanish (?additional languages pending app translation)
✓. Access to or ownership of a smartphone compatible with Malama
✓. Willing and able to sign the informed consent
Exclusion criteria
✕. Unable to tolerate oral glucose tolerance test (i.e. history of gastric bypass surgery)
✕. Diagnosis of pregestational diabetes
✕. Prescribed medications for chronic disease that affect glucose metabolism (e.g., long term oral steroids)